Os nanomateriais e a descoberta de novos mundos na bancada do químico

In recent years there has been great progress in the field of nanotechnology largely driven by research into nanomaterials. Chemistry appears in this context for its relevant role in the synthesis and surface modification of nanomaterials. This review article discusses fundamental concepts related to the synthesis and properties of inorganic nanoparticles with diverse properties. Aspects related to unique size dependent optical and magnetic properties are discussed and the chemistry involved in the preparation of nanomaterials reviewed. Fundamental aspects of the chemical modification of nanoparticles envisaging potential applications for these materials are also addressed.

Nanocompósito de polpa de mamão e nanopartículas de quitosana para aplicação em embalagens

Nanocomposite materials have been incorporated into biopolymers, (e.g. hydroxypropyl methylcellulose), to improve their physical and chemical properties and enable them to be applied in food packaging, especially for their biodegradable and renewable properties. With this addition, fruit puree has been incorporated into the films to confer nutritional properties besides color and flavor. Chitosan is of interest in the packaging field since it is a biodegradable, bioabsorbable, antimicrobial agent. Furthermore, chitosan nanoparticles have been widely explored for their interesting properties and potential applications in food packaging. This work was divided into two stages: (1) chitosan nanoparticle synthesis; (2) addition of nanoparticles into HPMC and papaya puree films. Addition of chitosan nanoparticles to HPMC and papaya puree films improved film properties: mechanical, thermal and water vapor barrier. We have developed a novel nanomaterial with great potential for application in packaging to prolong the shelf life of food.

APLICAÇÃO DE ÓXIDOS DE FERRO NANOESTRUTURADOS COMO ADSORVENTES E FOTOCATALISADORES NA REMOÇÃO DE POLUENTES DE ÁGUAS RESIDUAIS

New techniques for treating wastewater, particularly the removal or degradation of organic pollutants and heavy metals, among other pollutants, have been extensively studied. The use of nanostructured iron oxides as adsorbent and photocatalyst for the removal of these contaminants has proved a promising approach, not only because of their high treatment efficiency, but also for their cost-effectiveness, having the flexibility for in situ and ex situ applications. In this review, we briefly introduced the most used kinds of iron oxide nanoparticles, some synthesis techniques for iron oxide nanostructure formation, their potential benefits in environmental clean-up, and their recent advances and applications in wastewater treatment. These advances range from the direct applications of synthesized nanoparticles as adsorbents for removing toxic contaminants or as catalysts to oxidize and break down noxious contaminants (including bacteria and viruses) in wastewater, to integrating nanoparticles into conventional treatment technologies, such as composite photocatalytic filters (membranes, sand and ceramic) that combine separation technology with photocatalytic activity. Finally, the impact of nanoparticles on the environment and human health is briefly discussed.

Imazapyr root exudation from eucalypt seedlings cultivated in nutritive solution

Imazapyr has been used in Brazilian eucalypt cultivation for the maintenance of clearings and coppicing control in areas undergoing stand reform. However, inquiries have been made as to the final fate of the molecule. Imazapyr root exudation in eucalypt plants was evaluated through a bioassay under greenhouse conditions, by applying different herbicide doses (0.000, 0.375, 0.750, 1.125, and 1.500 kg ha-1 a.i.) on Eucalyptus grandis seedlings derived from vegetative propagation, hydroponically cultivated in 2.500 ml vases. Forty-day-old seedlings of the same clone were used as bioindicators, transplanted to the vases two days after herbicide application. After a period of 13 days of coexistence, the sprayed plants were removed and discarded; ten days later, the visual symptoms of toxicity were evaluated and the total dry biomass (aerial part and roots) of the bioindicators were determined. The lowest herbicide dose (0.375 kg ha-1 a.i.) affected the total biomass and growth, being most evident in the aerial part, with larger I50 for root dry biomass. The E. grandis seedlings exuded imazapyr, and/or its metabolites, in concentrations capable of affecting the growth of plants of the same species.

Cell therapy in dilated cardiomyopathy: from animal models to clinical trials

Dilated cardiomyopathy can be the end-stage form and common denominator of several cardiac disorders of known cause, such as hypertensive, ischemic, diabetic and Chagasic diseases. However, some individuals have clinical findings, such as an increase in ventricular chamber size and impaired contractility (classical manifestations of dilated cardiomyopathy) even in the absence of a diagnosed primary disease. In these patients, dilated cardiomyopathy is classified as idiopathic since its etiology is obscure. Nevertheless, regardless of all of the advances in medical, pharmacological and surgical procedures, the fate of patients with dilated cardiomyopathy (of idiopathic or of any other known cause) is linked to arrhythmic episodes, severe congestive heart failure and an increased risk of sudden cardiac death. In this review, we will summarize present data on the use of cell therapies in animal models of dilated cardiomyopathies and will discuss the few clinical trials that have been published so far involving patients affected by this disease. The animal models discussed here include those in which the cardiomyopathy is produced by genetic manipulation and those in which disease is induced by chemical or infectious agents. The specific model used clearly creates restrictions to translation of the proposed cell therapy to clinical practice, insofar as most of the clinical trials performed to date with cell therapy have used autologous cells. Thus, translation of genetic models of dilated cardiomyopathy may have to wait until the use of allogeneic cells becomes more widespread in clinical trials of cell therapies for cardiac diseases.